<DOC>
	<DOCNO>NCT02322788</DOCNO>
	<brief_summary>A randomised , double-blind , double-dummy , multi-site , phase III , single dose , 4-way cross-over pharmacodynamic study evaluate efficacy Bricanyl Turbuhaler M3 compare Bricanyl Turbuhaler M2 study protective effect methacholine induce bronchoconstriction patient stable , mild moderate asthma</brief_summary>
	<brief_title>Comparing Efficacy Bricanyl M2 Bricanyl M3 0.5 1.5 mg Dose Levels , Allow Switch From Bricanyl Turbuhaler M2 Bricanyl Turbuhaler M3</brief_title>
	<detailed_description>The study include female male patient , 18 65 year old , stable , mild moderate asthma short act β2-agonist ( SABA ) alone , low dose inhale corticosteroid ( ICS ) ( 200-400 µg budesonide correspond ) combination low dose ICS long act β2-agonists ( LABA ) . Approximately 60 patient randomise order 49 complete . The primary objective demonstrate therapeutic equivalence Bricanyl Turbuhaler M3 Bricanyl Turbuhaler M2 use bronchoprotective effect . Outcome measure : PC20 ( Methacholine provocative concentration cause 20 % drop FEV1 ) . The safety objective compare safety Bricanyl Turbuhaler M2 Bricanyl Turbuhaler M3 . Outcome measure Adverse Events/Serious . Study period Q1 2015 - Q1 2016 .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>Female male age 18 65 year . At least 6 month document clinical diagnosis asthma define GINA 2012 American Thoracic Society ( Expert Panel Report 3 2007 ) prior visit 1 Stable asthmatic SABA alone , low dose ICS ( 200400 µg budesonide correspond ) fix combination low ICS/LABA At enrolment visit 1a , visit baseline FEV1 must ≥80 % predict normal ( NHANES III ) . For LABA patient visit baseline FEV1 must ≥80 % predict normal ( NHANES III ) visit 1a visit 1b . If , patient withdrawn study At enrolment visit 1a 1b ( LABA patient ) end runin period , visit 2 , eligible patient demonstrate airway responsiveness methacholine PC20 &lt; 8 mg/mL . If , patient withdrawn study Capable use Turbuhaler inhalation device judge investigator . Exclusion Criteria : Diagnosed COPD history cystic fibrosis , bronchiectasis respiratory disease Pregnancy , breastfeeding , lactation , plan pregnancy study . Fertile woman use acceptable contraceptive measure Conditions could alter airway reactivity methacholine ( e.g . pneumonia , upper respiratory tract infection , viral bronchitis and/or sinobronchitis ) within past six week Exacerbation due asthma change asthma medication last 3 month prior enrolment Night time awakening due asthma symptom 2 consecutive night last 4 week prior enrolment Smokers 6 month prior study start history smoke 10 pack year ( e.g . 20 cigarettes/day least 10 year , 10 cigarettes/day least 20 year , equal ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Inhalation , Pharmacodynamic , Patients ,</keyword>
</DOC>